Skip to main content

Table 4 Outcomes of the tumour with intravesical BCG

From: Complications of intravesical BCG therapy in non-muscle invasive bladder cancer: our tertiary care centre experience

Outcome

Symptoms

Number of the patients

Completed BCG therapy without any adverse effects

No symptoms

42 (28.2%)

Completed BCG therapy with mild adverse effects

Mild irritative voiding symptoms, mild haematuria, fever < 38.5 °C

33 (22.14%)

Completed BCG therapy with dose reduction

Severe irritative voiding symptoms, haematuria, or symptoms lasting > 48 h

21 (14.1%)

Stopped BCG due to

 1. Adverse effects (moderate/severe)

Allergic Reactions (Joint Pain, Rash)

23 (15.4%)

Organ Involvement (Epididymis, Liver, Lung, Kidney, Bone, Joint, Prostate)

 

 2. Disease progression

Tumour is progressing

10 (6.7%)

 3. BCG refractory disease

Tumour is present at 3 months, CIS is present at both 3 and 6 months

7 (4.6%)

 4. Recurrence during BCG

Tumour recurrence after initial response

5 (3.3%)

 5. Patients’ not willing for BCG continuation

 

8 (5.3%)